KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

GoodRx Holdings (GDRX) Receivables Refunds (2020 - 2022)

GoodRx Holdings' Receivables Refunds history spans 3 years, with the latest figure at $4.5 million for Q4 2022.

  • For Q4 2022, Receivables Refunds fell 45.7% year-over-year to $4.5 million; the TTM value through Dec 2022 reached $4.5 million, down 45.7%, while the annual FY2022 figure was $4.5 million, 45.7% down from the prior year.
  • Receivables Refunds for Q4 2022 was $4.5 million at GoodRx Holdings, down from $16.8 million in the prior quarter.
  • Across five years, Receivables Refunds topped out at $79.8 million in Q2 2021 and bottomed at $4.5 million in Q4 2022.
  • The 3-year median for Receivables Refunds is $16.8 million (2022), against an average of $24.5 million.
  • The largest YoY upside for Receivables Refunds was 45.7% in 2022 against a maximum downside of 79.0% in 2022.
  • A 3-year view of Receivables Refunds shows it stood at $28.6 million in 2020, then crashed by 70.83% to $8.3 million in 2021, then tumbled by 45.7% to $4.5 million in 2022.
  • Per Business Quant, the three most recent readings for GDRX's Receivables Refunds are $4.5 million (Q4 2022), $16.8 million (Q2 2022), and $5.8 million (Q1 2022).